Hardened Hope: Care Advances for Patients with Fibrodysplasia Ossificans Progressiva
- CME / AMA PRA Category 1 Credit™
- MOC / ABP MOC Points
As a rare disease, fibrodysplasia ossificans progressiva (FOP) poses substantial diagnostic and treatment challenges for pediatricians and pediatric orthopedists. It is frequently confused with other development bone diseases due to similar presentation, and treatment options are lacking. Currently, treatment of FOP is limited to symptomatic management of disease flare-ups. In recent years, however, improved understanding of the genetics and pathophysiology of FOP have led to improvements in diagnosis and treatment, as well as the identification of multiple new therapeutic targets. Novel agents that have demonstrated efficacy in minimizing disease symptoms and slowing progression of disease are currently in late-stage clinical trials and may soon be available for FOP treatment.
This activity, Hardened Hope: Care Advances for Patients with Fibrodysplasia Ossificans Progressiva, will provide clinicians with expert advice and guidance on how to identify and diagnose FOP in their patients, current best practices for FOP management, and the most up-to-date information on novel therapies currently in clinical trial for treatment of FOP.
Welcome and Introduction
Increasing Awareness of FOP
Ensuring Optimal FOP Treatment
Understanding the Latest Advances in FOP Care
Q&A Session and Activity Roundup
The intended audiences for this initiative are pediatricians and pediatric orthopedists, the clinicians who diagnose and manage patients with FOP.
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.
At the conclusion of this education, participants should be able to:
- Distinguish patients with FOP using the latest recommendations and criteria
- Develop effective FOP treatment plans which incorporate the most recent clinical evidence
- Evaluate the latest safety and efficacy data with FOP agents in late-stage development
Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physicians – The Potomac Center for Medical Education designates this enduring materials for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this activity, please email: email@example.com.
The Hospital for Sick Children and Peter Gilgan Centre for Research and Learning
Chair of Medical Genetics
University of Alberta
Clinical Assistant Professor
Department of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
ABP PART 2 DESIGNATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. To receive MOC points, you MUST complete the posttest and evaluation. For ABP MOC points, your information will be shared with the ABP through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABP records. For questions regarding CME credit or the evaluation, please email firstname.lastname@example.org.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
Anna Rabinowitz, MD, CPPS: Nothing to disclose
NON-FACULTY CONTENT CONTRIBUTORS
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This program is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.
Understanding and Addressing the Global Spread of the COVID-19 Infection: A Clinician’s Guide
Credits 1.00 (60 min)
Obesity and COVID-19 in the Outpatient Setting: What Clinicians Need to Know
Credits 1.00 (60 min)
Expert Updates on Diagnosing and Managing Eosinophilic Granulomatosis with Polyangiitis
Credits 1.00 (60 min)